Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117082) titled 'A multicenter, prospective, observational cohort study comparing lenvatinib mesylate and tislelizumab in combination with RALOX-HAIC versus combination with FOLFOX-HAIC for the treatment of advanced hepatocellular carcinoma' on Jan. 20.
Study Type: Observational study
Study Design:
Case-Control study
Primary Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Condition:
Hepatocellular carcinoma
Intervention:
FOLFOX-HAIC group (Hepatic Artery Infusion Chemotherapy):NA
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-01-20
Target S...